BOLD
BOLD clinical trials: Boundless Bio, Inc.
Every trial on ClinicalTrials.gov where Boundless Bio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BOLD on the catalyst calendar · BOLD registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Actual | NCT07408089Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerBoundless Bio, Inc. · Breast Cancer | BOLDLead | Phase 1 | Terminated | Locked | Locked | Locked |
| Mar 17, 2026Actual | NCT05827614Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With...Boundless Bio, Inc. · Triple Negative Breast Cancer (TNBC) | BOLDLead | Phase 1 | Terminated | Locked | Locked | Locked |
| Jun 25, 2025Actual | NCT06299761Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene AmplificationsBoundless Bio, Inc. · Solid Tumor | BOLDLead | Phase 1 | Terminated | Locked | Locked | Locked |
- Primary completion Jul 28, 2026ActualPhase 1NCT07408089Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerBoundless Bio, Inc. · Breast CancerTerminatedBOLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2026ActualPhase 1NCT05827614Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With...Boundless Bio, Inc. · Triple Negative Breast Cancer (TNBC)TerminatedBOLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2025ActualPhase 1NCT06299761Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene AmplificationsBoundless Bio, Inc. · Solid TumorTerminatedBOLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner